Colon Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of colon cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in which
Colorectal Cancer Screening (PDQ®): Screening - Health Professional Information [NCI] - Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site's Contact Form. We can respond only to email messages written in English.
Rectal Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview
Primary Surgical TherapyThe primary treatment for patients with rectal cancer is surgical resection of the primary tumor. Local excision of clinical T1 tumors is an acceptable surgical technique for appropriately selected patients. For all but T1 tumors, a mesorectal excision is the treatment of choice. Very selected patients with T2 tumors may be candidates for local excision. Local failure rates in the range of 4% to 8% following rectal resection with appropriate mesorectal excision (total mesorectal excision [TME] for low/middle rectal tumors and mesorectal excision at least 5 cm below the tumor for high rectal tumors) have been reported.[1,2,3,4,5]The low incidence of local relapse following meticulous mesorectal excision has led some investigators to question the routine use of adjuvant radiation therapy. Because of an increased tendency for first failure in locoregional sites only, the impact of perioperative radiation therapy is greater in rectal
Colon Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Colon Cancer
Related Summaries Note: Other PDQ summaries containing information related to colon cancer include the following: Colorectal Cancer Screening Colorectal Cancer Prevention Genetics of Colorectal Cancer Unusual Cancers of Childhood Treatment (childhood cancer of the colon) Statistics Note: Estimated new cases and deaths from colon cancer in the United States in 2010:[ 1 ] New cases: 102,900 (colon ...
Colorectal Cancer Screening (PDQ®): Screening - Patient Information [NCI] - Colorectal Cancer Screening
Tests are used to screen for different types of cancer.Some screening tests are used because they have been shown to be helpful both in finding cancers early and decreasing the chance of dying from these cancers. Other tests are used because they have been shown to find cancer in some people; however, it has not been proven in clinical trials that use of these tests will decrease the risk of dying from cancer. Scientists study screening tests to find those with the fewest risks and most benefits. Cancer screening trials also are meant to show whether early detection (finding cancer before it causes symptoms) decreases a person's chance of dying from the disease. For some types of cancer, finding and treating the disease at an early stage may result in a better chance of recovery. Clinical trials that study cancer screening methods are taking place in many parts of the country. Information about ongoing clinical trials is available from the NCI Web site.Studies show that screening for
Colon Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - Changes to This Summary (07 / 07 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.Editorial changes were made to this summary.
Colon Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage I Colon Cancer Treatment
Because of its localized nature, stage I colon cancer has a high cure rate.Standard Treatment Options for Stage I Colon CancerSurgeryStandard treatment options for stage I colon cancer include the following:Wide surgical resection and anastomosis.Evidence (laparoscopic techniques):The role of laparoscopic techniques [1,2,3,4] in the treatment of colon cancer was examined in a multicenter, prospective, randomized trial (NCCTG-934653, now closed) comparing laparoscopic-assisted colectomy (LAC) with open colectomy.Three-year recurrence rates and 3-year overall survival rates were similar in the two groups. (Refer to the Primary Surgical Therapy section in the Treatment Option Overview section of this summary for more information.)The quality-of-life component of this trial has been published and minimal short-term quality-of-life benefits with LAC were reported.[Level of evidence: 1iiC]Current Clinical TrialsCheck for U.S. clinical trials from NCI's list of cancer clinical trials
Colorectal Cancer Prevention (PDQ®): Prevention - Patient Information [NCI] - Colorectal Cancer Prevention
Avoiding risk factors and increasing protective factors may help prevent cancer.Avoiding cancer risk factors may help prevent certain cancers. Risk factors include smoking, being overweight, and not getting enough exercise. Increasing protective factors such as quitting smoking, eating a healthy diet, and exercising may also help prevent some cancers. Talk to your doctor or other health care professional about how you might lower your risk of cancer.The following risk factors increase the risk of colorectal cancer:AgeThe risk of colorectal cancer increases after age 50. Most cases of colorectal cancer are diagnosed after age 50.Family history of colorectal cancerHaving a parent, brother, sister, or child with colorectal cancer doubles a person's risk of colorectal cancer.Personal historyHaving a personal history of inflammatory bowel disease increases the risk of colorectal cancer. Inherited riskThe risk of colorectal cancer is increased when certain gene changes linked to familial
Colon Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage IV and Recurrent Colon Cancer Treatment
Stage IV colon cancer denotes distant metastatic disease. Treatment of recurrent colon cancer depends on the sites of recurrent disease demonstrable by physical examination and/or radiographic studies. In addition to standard radiographic procedures, radioimmunoscintography may add clinical information that may affect management. Such approaches have not led to improvements in long-term outcome measures such as survival.Treatment Options for Stage IV and Recurrent Colon CancerTreatment options for stage IV and recurrent colon cancer include the following:Surgical resection of locally recurrent cancer.Surgical resection and anastomosis or bypass of obstructing or bleeding primary lesions in selected metastatic cases.Resection of liver metastases in selected metastatic patients (5-year cure rate for resection of solitary or combination metastases exceeds 20%) or ablation in selected
Colorectal Cancer Prevention (PDQ®): Prevention - Health Professional Information [NCI] - Description of the Evidence
BackgroundIncidence and mortalityColorectal cancer (CRC) is the third most common malignant neoplasm worldwide  and the second leading cause of cancer deaths (irrespective of gender) in the United States. It is estimated that there will be 142,820 new cases diagnosed in the United States in 2013 and 50,830 deaths due to this disease. Between 2005 and 2009, CRC incidence rates in the United States declined by 4.1% per year among adults aged 50 years and older. For the past 20 years, the mortality rate has been declining in both men and women. Between 2005 and 2009, the mortality rate declined by 2.4% per year in men and by 3.1% per year in women. In adults younger than 50 years, CRC incidence rates increased by about 1.1% per year. The overall 5-year survival rate is 64%. About 5% of Americans are expected to develop the disease